# A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

> **NCT01709305** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 5570 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Metformin
- **DRUG:** Sitagliptin
- **DRUG:** Acarbose
- **DRUG:** Repaglinide
- **DRUG:** Glimepiride
- **DRUG:** Gliclazide

## Key facts

- **NCT ID:** NCT01709305
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-08
- **Primary completion:** 2015-04-17
- **Final completion:** 2015-04-17
- **Target enrollment:** 5570 (ACTUAL)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709305, "A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01709305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*